Novo Nordisk’s next-generation weight-loss drug CagriSema
2024年12月20日 · Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in...
Novo Nordisk shares plunge 20% after disappointing trial results; …
2024年12月20日 · Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 24% at one point Friday after reporting trial results that missed expectations.
Novo Nordisk shares plunge after CagriSema obesity drug trial ...
2024年12月20日 · Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.
Latest news - Novo Nordisk
2024年12月18日 · We plan to invest 2.9 billion Danish kroner to establish a cutting-edge quality control laboratory in Hillerød, Denmark. Environmental challenges have never been more critical or more urgent than they are today. But at Novo Nordisk, we never allow complexity to become a barrier to change.
Company announcements & press releases - Novo Nordisk
Product-related press releases will only be available upon request after three weeks of publication on our website in order to comply with applicable regulation.
Compounded semaglutide associated with at least 10 deaths, Novo Nordisk …
2024年11月6日 · Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have been associated with at least 100 hospitalizations and 10 deaths, the chief...
News Details - novonordisk.com
6 天之前 · Novo Nordisk Media: Ambre James-Brown +45 3079 9289 [email protected]: Liz Skrbkova (US) +1 609 917 0632 [email protected]: Novo Nordisk investors: Jacob Martin Wiborg Rode +45 3075 5956 [email protected]: David Heiberg Landsted +45 3077 6915 [email protected]: Sina Meyer +45 3075 6656 [email protected]: Ida …
Novo Nordisk U.S. News & Media Hub | Novo Nordisk U.S.
View financial meetings and events, strategic aspirations for 2025 and contact information for investor relations. A place to find different points of view from inside Novo Nordisk and the communities we serve. Welcome to Novo Nordisk's U.S. news and media hub.
Novo Nordisk Sinks on Disappointing Trial Results for
2024年12月20日 · Novo Nordisk's (NVO) U.S.-listed shares sank over 19% in premarket trading Friday after releasing trial results for its next generation of weight loss drug, meant to add to its current lineup of...
Ozempic maker Novo Nordisk, after trial disappointment, …
6 天之前 · Novo Nordisk said an agreement reached last year with privately held Lexington, Mass. company Valo Health that initially was valued at up to $2.7 billion is now been expanded to a $4.6 billion deal.